XORTX Therapeutics Inc. Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Related party transactions (Tables)

Related party transactions (Tables)

12 Months Ended

Dec. 31, 2024

Related party transactions

Schedule of Management and directors' key management compensation transactions


		Management				Share-based
		Compensation		Directors’ fees		payments		Total
		$		$		$		$
Year ended December 31, 2022
Directors and officers		880,387		127,053		404,573		1,412,013

Year ended December 31, 2023
Directors and officers		974,240		182,675		77,779		1,234,694

Year ended December 31, 2024
Directors and officers		815,935		172,229		85,680		1,073,845